Frédéric Collet is graduated from the Institute of Political Sciences and University of Paris 2.
He starts his career in the cosmetic industry (Henkel Group), in France and the UK, he joined Novartis group’s in 2005 and its Ophthalmology activity as Ciba-Vision’s General Manager.
In 2009, he becomes President of Sandoz France (generic and biosimilar drugs).
In 2015, he is appointed as General Manager of Novartis Oncology in France and contributes to the development of the activity of this new strategic division in the Group. He completes the GSK oncology activity integration and the deployment of the portfolio in the areas of hematology, oncology and rare diseases.
Frederic Collet was appointed Novartis France Country President since April 1st, 2017. He leads the Country Executive Committee of the Group, including Novartis Pharma and Oncology, Sandoz and the industrial Biotechnological site of Huningue. However, he remains General Manager for Novartis Oncology in France, administrator of AAA, Advanced Accelerator Applications, owned by Novartis, and President of Cell for Cure, acquired by Novartis in 2019.
After being Secretary of the Leem Bureau and Board of Directors, Leader of the European Family, he was elected President of the Leem in July 2019.